480 related articles for article (PubMed ID: 31901237)
21. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
[TBL] [Abstract][Full Text] [Related]
22. SPOP suppresses tumorigenesis by regulating Hedgehog/Gli2 signaling pathway in gastric cancer.
Zeng C; Wang Y; Lu Q; Chen J; Zhang J; Liu T; Lv N; Luo S
J Exp Clin Cancer Res; 2014 Sep; 33(1):75. PubMed ID: 25204354
[TBL] [Abstract][Full Text] [Related]
23. Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP.
Sabri N; Cuneo MJ; Marzahn MR; Lee J; Bouchard JJ; Güllülü Ö; Vaithiyalingam S; Borgia MB; Schmit J; Mittag T
J Biol Chem; 2023 Dec; 299(12):105427. PubMed ID: 37926283
[TBL] [Abstract][Full Text] [Related]
24. The diverse roles of SPOP in prostate cancer and kidney cancer.
Wang Z; Song Y; Ye M; Dai X; Zhu X; Wei W
Nat Rev Urol; 2020 Jun; 17(6):339-350. PubMed ID: 32355326
[TBL] [Abstract][Full Text] [Related]
25. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
[TBL] [Abstract][Full Text] [Related]
26. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract][Full Text] [Related]
27. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
[TBL] [Abstract][Full Text] [Related]
29. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.
Li G; Ci W; Karmakar S; Chen K; Dhar R; Fan Z; Guo Z; Zhang J; Ke Y; Wang L; Zhuang M; Hu S; Li X; Zhou L; Li X; Calabrese MF; Watson ER; Prasad SM; Rinker-Schaeffer C; Eggener SE; Stricker T; Tian Y; Schulman BA; Liu J; White KP
Cancer Cell; 2014 Apr; 25(4):455-68. PubMed ID: 24656772
[TBL] [Abstract][Full Text] [Related]
30. SPOP suppresses testicular germ cell tumors progression through ubiquitination and degradation of DPPA2.
Wang J; Zhuang H; Zhang H; Li Q; Cao X; Lin Z; Lin T; Chen X; Ni X; Yang J; Zhao Y; Shen L; Wang H; Zhu J; Ye M; Jin X
Biochem Biophys Res Commun; 2021 Jun; 557():55-61. PubMed ID: 33862460
[TBL] [Abstract][Full Text] [Related]
31. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
32. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
33. Cullin 3 and Its Role in Tumorigenesis.
Chen RH
Adv Exp Med Biol; 2020; 1217():187-210. PubMed ID: 31898229
[TBL] [Abstract][Full Text] [Related]
34. Structural basis of high-order oligomerization of the cullin-3 adaptor SPOP.
van Geersdaele LK; Stead MA; Harrison CM; Carr SB; Close HJ; Rosbrook GO; Connell SD; Wright SC
Acta Crystallogr D Biol Crystallogr; 2013 Sep; 69(Pt 9):1677-84. PubMed ID: 23999291
[TBL] [Abstract][Full Text] [Related]
35. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
[TBL] [Abstract][Full Text] [Related]
36. Coordinated activation of the nuclear ubiquitin ligase Cul3-SPOP by the generation of phosphatidylinositol 5-phosphate.
Bunce MW; Boronenkov IV; Anderson RA
J Biol Chem; 2008 Mar; 283(13):8678-86. PubMed ID: 18218622
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
Nikhil K; Haymour HS; Kamra M; Shah K
Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589
[TBL] [Abstract][Full Text] [Related]
38. Structure-Activity Relationship of SPOP Inhibitors against Kidney Cancer.
Dong Z; Wang Z; Guo ZQ; Gong S; Zhang T; Liu J; Luo C; Jiang H; Yang CG
J Med Chem; 2020 May; 63(9):4849-4866. PubMed ID: 32297747
[TBL] [Abstract][Full Text] [Related]
39. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
[TBL] [Abstract][Full Text] [Related]
40. The emerging role of speckle-type POZ protein (SPOP) in cancer development.
Mani RS
Drug Discov Today; 2014 Sep; 19(9):1498-502. PubMed ID: 25058385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
